Suggestions
Suzanne Brewerton
Proven data, software and analytics Leader. Passionate about using data and technology to improve lives.
Professional Background
Suzanne Brewerton is a seasoned expert in the domains of data science, analytics, and computational biology, currently serving as the Head of Data and Analytics at WaveBreak, a prestigious biotech company dedicated to drug discovery and development for protein misfolding diseases. With over 20 years of extensive experience, Suzanne has honed her skills in applying advanced data science methodologies to deepen our understanding and enhance the treatment of complex diseases. Her leadership at WaveBreak reflects her commitment to integrating comprehensive data and analytics across various domains, ultimately fostering innovation in the biotech industry.
Throughout her career, Suzanne has successfully spearheaded multidisciplinary teams, adeptly navigating the landscapes of partnership and collaboration essential for advancing scientific endeavors. Her expertise in implementing modern data architectures has played a critical role in the delivery of data-driven software products that are pivotal to scientific advancement. Suzanne’s significant contributions to the field are further underscored by her effectiveness in bridging the gap between data analytics and practical applications, ensuring that powerful insights translate into actionable outcomes in drug development.
Education and Achievements
Suzanne's academic journey is as impressive as her career. She achieved a Doctor of Philosophy (PhD) in Computational Structural Biology from the prestigious University of Cambridge, a program known for its rigorous academic standards and cutting-edge research opportunities. This foundation in structural bioinformatics has provided her with an in-depth understanding of biological systems at the molecular level, a critical area of focus in her professional work.
In addition to her PhD, Suzanne holds a Bachelor of Science with Honors (BSc Hons) in Biochemistry from The University of Manchester. This educational background in biochemistry has equipped her with the essential knowledge required to dissect complex biological processes, thereby enabling her to contribute significantly to the fields of data science and biotech.
Suzanne’s early educational achievements include A-levels in Mathematics, Chemistry, Physics, and English from The Dame Alice Harpur School, reinforcing her robust analytical and critical thinking skills that are essential in her career. Over the years, she has also contributed to the scientific community by publishing numerous papers in peer-reviewed journals and participating in several patent applications, marking her as a thought leader in her field.
Career Highlights
Before stepping into her role at WaveBreak, Suzanne held several key positions in prominent organizations within the biotech and pharmaceutical landscape. At AstraZeneca, she was the Omics Platform Lead for R&D IT and previously led R&D IT efforts for their Oncology, Precision Medicine, and Genomics sectors. Her leadership in these roles was instrumental in leveraging data to drive drug discovery and development, utilizing her expertise in the intersection of data and biology to deliver exceptional results.
Furthermore, Suzanne has served as the Director of Bioinformatics at CXA Group and as a Group Leader of Bioinformatics at Human Longevity, Inc., where she led initiatives aimed at harnessing big data to better understand human health and longevity. Her experience as a Senior Informatics Research Scientist and Research Scientist at Eli Lilly and Company, as well as her earlier roles at Astex Therapeutics and Astex Technology, underscores her versatile experience across different facets of biotech and pharmaceuticals. Each role has contributed to her vast reservoir of knowledge and expertise, enabling her to make impactful strides in advancing drug discovery processes.
Personal Mission and Future Goals
Suzanne Brewerton’s mission focuses on leveraging data and analytics for acceleration in innovation within the biotech sector. As she continues to lead at WaveBreak, she aims to revolutionize how data is used to inform drug discovery and development strategies. Her ongoing commitment to collaboration and partnership signifies her belief in the power of collective expertise in addressing the complexities of protein misfolding diseases.
Looking ahead, Suzanne aspires to further enhance the integration of data-driven approaches in healthcare, potentially exploring the implications of new technological advancements and methodologies for improving patient outcomes. She remains dedicated to fostering an environment where science meets technology, ultimately championing the importance of data in crafting transformative solutions for biological challenges.
Conclusion
Suzanne Brewerton stands out as a leading figure in biotech, whose extensive background in data science and analytics propels her mission to innovate and impact the field of drug discovery. With a richly varied career that reflects a profound dedication to understanding complex diseases and a commitment to collaborative success, she continues to inspire those around her and significantly contribute to the ever-evolving landscape of biotechnology.